Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
99.60
-1.20 (-1.19%)
Oct 6, 2025, 10:42 AM CET
-1.19%
Market Cap496.39M
Revenue (ttm)n/a
Net Income (ttm)-14.00M
Shares Out4.92M
EPS (ttm)-2.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,105
Average Volume9,821
Open100.60
Previous Close100.80
Day's Range99.50 - 100.80
52-Week Range66.10 - 129.00
Beta1.26
RSI49.21
Earnings DateSep 18, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.